Kou Qin
InvestorInvestor at Eisai Innovation, Inc.
Boston, Massachusetts
Writes $100K – $5M checks · typically $1.5M
Experience
- TTM CapitalPartnercurrent2026 — presentShanghai & Boston
- AllyRNABoard Membercurrent2026 — presentHong Kong SAR
- Eisai Innovation IncSenior Director of Investment2026Cambridge, Massachusetts, United States
- Eisai Innovation IncManaging Director of Investment2023 — 2026Cambridge, Massachusetts, United States
- Eisai Innovation IncPrincipal of Investment2021 — 2022Cambridge, Massachusetts, United States
- Vivacta BiotechnologyBoard Observer2025 — 2026Shanghai, China
- ProTgen Inc.Board Observer2024 — 2026Toronto, Ontario, Canada
- eGenesis, Inc.Investor2024 — 2026Cambridge, Massachusetts, United States
- Iambic TherapeuticsInvestor2023 — 2026San Diego, California, United States
- Hyku BiosciencesBoard Observer2023 — 2026Cambridge, Massachusetts, United States
- Tune TherapeuticsInvestor2023 — 2026Seattle, Washington, United States
- Casma TherapeuticsBoard Observer2022 — 2026Cambridge, Massachusetts, United States
- RiboX TherapeuticsBoard Observer2022 — 2026Shanghai, China & Tel Aviv, Israel
- Ophidion BioBoard Observer2022 — 2026Pasadena, California, United States
- TraveraInvestor2021 — 2026San Mateo, California, United States
- 炎明生物 Pyrotech TherapeuticsSeed Investor2020 — 2026Beijing, China
- Kernal BiologicsSeed Investor2020 — 2026Cambridge, Massachusetts, United States
- Orange HealthSeed Investor2020 — 2026Bengaluru, Karnataka, India
- Vitable HealthSeed Investor2020 — 2026Philadelphia, Pennsylvania, United States
- Excalipoint Therapeutics Inc.(艾科联生物科技)Board Observer2026Shanghai, China
Education
- Harvard UniversityMaster of Science (SM), Biostatistics2013 — 2015
- Y Combinator2016 F3 Batch2016
- Harvard Business SchoolCross-registered Core Program
- Medical College of Georgia at Augusta UniversityPhD, Pharmacology2006 — 2011
- Huazhong University of Science and TechnologyBE, Biomedical Engineering2002 — 2006
- Cornell University
Skills & more
Matlab7R4Python2Stata2SAS3Strategy1Oncology2Fundraising3Start-up Ventures2Investment Strategy1Drug Discovery1Drug Development
+12 more
Corporate StrategyBusiness StrategyInvestment StrategiesBusiness AnalysisMedical DiagnosticsLife SciencesPharmacologyNeuroscienceConfocal MicroscopyGenomicsBiostatisticsBioinformaticsLanguages Chinese · English
- Credential of Business Readiness — Harvard Business School
From Kou's professional profile.
Colleagues at Eisai Innovation, Inc.
Frequently asked questions
- Where does Kou Qin work?
- Kou Qin is Investor at Eisai Innovation, Inc..
- What check size does Kou Qin write?
- Kou Qin typically writes checks of $100K – $5M.
Same school
Also attended Harvard University1,457
Alfred LinPartner at Sequoia CapitalChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzSarah TavelVenture Partner at BenchmarkDanny RimerPartner at Index VenturesLaela SturdyManaging Partner at CapitalGRyan IsonoDeal Partner at Felicis Ventures
+ 1,451 more
Also attended Y Combinator2,000
Maroof AhmedFounder at Octopus VenturesJustin SwartPartner at Bitkraft Esports VenturesVictor SantosVictor Scout at One Way VenturesSwapnil JainCEO, Observe.AI at EMERGENT VENTURESChase AdamPartner at Very Serious VenturesMuzzammil (MZ) ZaveriPartner at Audacious Ventures backing ambitious early-stage founders
+ 1,994 more
Also attended Medical College of Georgia at Augusta University2
Also attended Cornell University703
Doug LeonePartner at Sequoia Capital; former Global Managing PartnerJenny LeeSenior Managing Partner at Granite AsiaNeeraj AgrawalGeneral Partner at Battery VenturesMichelle FernandesInvestor at Index VenturesMicah RosenbloomGeneral Partner at Founder CollectiveAlexandra FarmerPrincipal at Intel Capital, North America
+ 697 more
Shared employers
Also worked at Kernal Biologics4
Also worked at MSA Capital1
Also worked at Harvard University273
Rachel HansenInvestor at Index VenturesDave MunichielloInvestor at GV (Google Ventures)Logan HilleLife Sciences Analyst at CincyTechWalter KowtoniukInvestor at Third Rock VenturesJefte DrijversInvestor at Third Rock VenturesSamuel ArbesmanVenture Partner at Lux Capital
+ 267 more






























)





